secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001641172-25-009273
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Q1 revenue $11.5M (+13% YoY); guides FY2025 ~$38M
-----------------------------------------------------------

- Net revenue $11.5M (+13% YoY); income from continuing ops $1.8M vs $0.8M.
- Thyroid revenue $8.0M (+19% YoY) to record; test volume up 16%.
- Cash collections $11.3M (+10% YoY) to record; adjusted EBITDA $2.1M vs $1.2M.
- Initiates FY2025 revenue guidance of approx. $38M despite PancraGEN loss after May 2.
- Gross profit margin improved to 64% from 62%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000164117225009273/0001641172-25-009273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000164117225009273/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer